Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project): Protocol for Two Systematic Literature Reviews, EDelphi Surveys and Online Consensus Meetings

Introduction: Meningioma is the most common primary intracranial tumour in adults. The majority are non-malignant, but a proportion behave more aggressively. Incidental/minimally symptomatic meningioma are often managed by serial imaging. Symptomatic meningioma, those that threaten neurovascular structures, or demonstrate radiological growth, are usually resected as first-line management strategy. For patients in poor clinical condition, or with inoperable, residual or recurrent disease, radiotherapy is often used as primary or adjuvant treatment. Effective pharmacotherapy treatments do not currently exist. There is heterogeneity in the outcomes measured and reported in meningioma clinical studies. Two 'Core Outcome Sets' (COS) will be developed: (COSMIC: Intervention) for use in meningioma clinical effectiveness trials and (COSMIC: Observation) for use in clinical studies of incidental/untreated meningioma.

Methods And Analysis: Two systematic literature reviews and trial registry searches will identify outcomes measured and reported in published and ongoing (1) meningioma clinical effectiveness trials, and (2) clinical studies of incidental/untreated meningioma. Outcomes include those that are clinician reported, patient reported, caregiver reported and based on objective tests (eg, neurocognitive tests), as well as measures of progression and survival. Outcomes will be deduplicated and categorised to generate two long lists. The two long lists will be prioritised through two, two-round, international, modified eDelphi surveys including patients with meningioma, healthcare professionals, researchers and those in caring/supporting roles. The two final COS will be ratified through two 1-day online consensus meetings, with representation from all stakeholder groups.

Ethics And Dissemination: Institutional review board (University of Liverpool) approval was obtained for the conduct of this study. Participant eConsent will be obtained prior to participation in the eDelphi surveys and consensus meetings. The two systematic literature reviews and two final COS will be published and freely available.

Trial Registration Number: COMET study ID 1508.

Citing Articles

Cook W, Khalil F, Gillespie C, Helmy A Neurosurg Rev. 2025; 48(1):268.

PMID: 40011234 PMC: 11865157. DOI: 10.1007/s10143-025-03420-5.

How Delphi studies in the health sciences find consensus: a scoping review.

Schifano J, Niederberger M Syst Rev. 2025; 14(1):14.

PMID: 39810238 PMC: 11734368. DOI: 10.1186/s13643-024-02738-3.

Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.

Wang J, Landry A, Raleigh D, Sahm F, Walsh K, Goldbrunner R Neuro Oncol. 2024; 26(10):1742-1780.

PMID: 38695575 PMC: 11449035. DOI: 10.1093/neuonc/noae082.

The outcomes measured and reported in intracranial meningioma clinical trials: A systematic review.

Millward C, Keshwara S, Armstrong T, Barrington H, Bell S, Brodbelt A Neurooncol Adv. 2024; 6(1):vdae030.

PMID: 38596717 PMC: 11003530. DOI: 10.1093/noajnl/vdae030.

The outcomes measured and reported in observational studies of incidental and untreated intracranial meningioma: A systematic review.

Millward C, Islim A, Armstrong T, Barrington H, Bell S, Brodbelt A Neurooncol Adv. 2024; 6(1):vdae042.

PMID: 38596715 PMC: 11003528. DOI: 10.1093/noajnl/vdae042.

References

Goldbrunner R, Minniti G, Preusser M, Jenkinson M, Sallabanda K, Houdart E . EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016; 17(9):e383-91. DOI: 10.1016/S1470-2045(16)30321-7. View

Goldbrunner R, Stavrinou P, Jenkinson M, Sahm F, Mawrin C, Weber D . EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021; 23(11):1821-1834. PMC: 8563316. DOI: 10.1093/neuonc/noab150. View

Williamson P, Altman D, Blazeby J, Clarke M, Devane D, Gargon E . Developing core outcome sets for clinical trials: issues to consider. Trials. 2012; 13:132. PMC: 3472231. DOI: 10.1186/1745-6215-13-132. View

Sinha I, Smyth R, Williamson P . Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med. 2011; 8(1):e1000393. PMC: 3026691. DOI: 10.1371/journal.pmed.1000393. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Rogers L, Barani I, Chamberlain M, Kaley T, McDermott M, Raizer J . Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2014; 122(1):4-23. PMC: 5062955. DOI: 10.3171/2014.7.JNS131644. View

Khodyakov D, Chen C . Response changes in Delphi processes: why is it important to provide high-quality feedback to Delphi participants?. J Clin Epidemiol. 2020; 125:160-161. DOI: 10.1016/j.jclinepi.2020.04.029. View

Gargon E, Crew R, Burnside G, Williamson P . Higher number of items associated with significantly lower response rates in COS Delphi surveys. J Clin Epidemiol. 2018; 108:110-120. PMC: 6438267. DOI: 10.1016/j.jclinepi.2018.12.010. View

Mohammad M, Chavredakis E, Zakaria R, Brodbelt A, Jenkinson M . A national survey of the management of patients with incidental meningioma in the United Kingdom. Br J Neurosurg. 2017; 31(4):459-463. DOI: 10.1080/02688697.2017.1297765. View

10.

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

11.

Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson P . A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol. 2017; 96:84-92. PMC: 5854263. DOI: 10.1016/j.jclinepi.2017.12.020. View

12.

Jenkinson M . 'Meningiomics'-an integration of data on the patient, tumour, extent of resection and molecular pathology to optimise the management and follow-up for meningiomas. Acta Neurochir (Wien). 2019; 161(12):2551-2552. DOI: 10.1007/s00701-019-04102-0. View

13.

Murphy M, Black N, Lamping D, McKEE C, Sanderson C, Askham J . Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998; 2(3):i-iv, 1-88. View

14.

Brookes S, Macefield R, Williamson P, McNair A, Potter S, Blencowe N . Three nested randomized controlled trials of peer-only or multiple stakeholder group feedback within Delphi surveys during core outcome and information set development. Trials. 2016; 17(1):409. PMC: 4989325. DOI: 10.1186/s13063-016-1479-x. View

15.

Rogers L, Zhang P, Vogelbaum M, Perry A, Ashby L, Modi J . Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2017; 129(1):35-47. PMC: 5889346. DOI: 10.3171/2016.11.JNS161170. View

16.

Kirkham J, Davis K, Altman D, Blazeby J, Clarke M, Tunis S . Core Outcome Set-STAndards for Development: The COS-STAD recommendations. PLoS Med. 2017; 14(11):e1002447. PMC: 5689835. DOI: 10.1371/journal.pmed.1002447. View

17.

Jenkinson M, Javadpour M, Haylock B, Young B, Gillard H, Vinten J . The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. Trials. 2015; 16:519. PMC: 4650615. DOI: 10.1186/s13063-015-1040-3. View

18.

Ostrom Q, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan J . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020; 22(12 Suppl 2):iv1-iv96. PMC: 7596247. DOI: 10.1093/neuonc/noaa200. View

19.

Jenkinson M, Ali A, Islim A, Helmy A, Grant R . Letter to the Editor. Establishing the role of prophylactic antiepileptic drugs in glioma and meningioma surgery. J Neurosurg. 2019; 131(3):985-987. DOI: 10.3171/2019.1.JNS19134. View

20.

Preusser M, Silvani A, Le Rhun E, Soffietti R, Lombardi G, Sepulveda J . Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro Oncol. 2021; 24(5):755-767. PMC: 9071312. DOI: 10.1093/neuonc/noab243. View